Survival outcomes in patients with non-small-cell lung cancer treated with erlotinib.

摘要: Erlotinib is used to treat non-small-cell lung cancer (NSCLC). was subsidized on the Pharmaceutical Benefits Schedule in Australia for treatment of advanced stage (IIIB or IV) NSCLC (August 2008). In pivotal trial supporting initial subsidy, erlotinib increased overall survival (OS) by 2 months compared with placebo (adjusted hazard ratio, 0.70; 95% confidence interval: 0.58-0.85). We examined effectiveness a 'real-world' setting measuring outcomes patients treated two tertiary metropolitan public hospitals Queensland. extracted data from electronic oncology prescribing system (CHARM) prescribed (1 September 2009 1 February 2015). Survival estimates and analyses were generated using Kaplan-Meier curves. 134 received at least one dose during study period. At date extraction 113 had died. The median patient age 64 years 55% men. duration 2.0 months. OS 5.8 progression-free (time start disease progression death any cause) 3.6 use Queensland sites consistent support subsidy. somewhat less than (5.8 vs. 6.7 months), which could be because hospital cohort including frailer who unsuitable parenteral chemotherapy, mixed epidermal growth factor receptor mutation status cohort.